Wells Fargo upgraded Cardinal Health from Underweight to Equal Weight and set a new price target of $127.00 from $101.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/5/2025 | $140.00 → $150.00 | Hold → Buy | Jefferies |
| 1/8/2025 | $130.00 → $144.00 | Hold → Buy | TD Cowen |
| 1/7/2025 | $140.00 | In-line → Outperform | Evercore ISI |
| 1/6/2025 | $132.00 → $145.00 | Neutral → Buy | BofA Securities |
| 12/13/2024 | $101.00 → $127.00 | Underweight → Equal Weight | Wells Fargo |
| 12/4/2024 | $139.00 | Outperform | Mizuho |
| 2/26/2024 | $125.00 | Outperform | Leerink Partners |
| 2/9/2024 | Hold → Buy | Argus |
Jefferies upgraded Cardinal Health from Hold to Buy and set a new price target of $150.00 from $140.00 previously
TD Cowen upgraded Cardinal Health from Hold to Buy and set a new price target of $144.00 from $130.00 previously
Evercore ISI upgraded Cardinal Health from In-line to Outperform and set a new price target of $140.00
DUBLIN, Ohio, May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an op
Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expirationGAAP1 operating earnings were $730 million; GAAP diluted EPS was $2.10Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00GI Alliance announces expansion into urology specialty therapeutic areaDUBLIN, Ohio, May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion,
MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE:CAH, Cardinal Health)) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer in the United States (U.S.). Following recent U.S. Food and Drug Administration (FDA) approval2, and in preparation for commercial launch in H1 2025, Telix has contracted with Cardinal Health to enable availability acr
DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e
RPM International Inc. (NYSE:RPM) today announced the appointment of three individuals, Craig S. Morford, Christopher L. Mapes and Julie A. Beck, to its board of directors. These appointments reflect RPM's ongoing commitment to expanding the expertise, diversity and leadership capabilities of its board as the company continues to drive long-term growth and shareholder value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113146614/en/Christopher L. Mapes (Photo: Business Wire) The appointments of Mr. Morford and Mr. Mapes are effective immediately, and Ms. Beck's term is set to commence on April 7, 2025. With these additions,
DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmac
10-Q - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
DUBLIN, Ohio, May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an op
Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expirationGAAP1 operating earnings were $730 million; GAAP diluted EPS was $2.10Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00GI Alliance announces expansion into urology specialty therapeutic areaDUBLIN, Ohio, May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion,
DUBLIN, Ohio, Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nucle
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
3 - CARDINAL HEALTH INC (0000721371) (Issuer)